Immunocore Reports 29.2% Revenue Growth in Q3 2025, Despite Net Loss

Immunocore Holdings plc reported significant financial results for the third quarter and the first nine months of 2025, showcasing a notable increase in revenue driven primarily by the sales of its lead product, KIMMTRAK. For the three months ended September 30, 2025, the company generated total revenue of $103.7 million, a 29.2% increase from $80.2 million in the same period of 2024. For the nine months ended September 30, 2025, total revenue reached $295.5 million, up 30.8% from $226.2 million year-over-year. The increase in revenue was attributed to higher sales volumes in the United States and Europe, as well as the expansion of KIMMTRAK into additional markets.

Despite the revenue growth, Immunocore reported a net loss of $0.2 million for the third quarter of 2025, a decrease from a net income of $8.7 million in the same quarter of 2024. For the nine-month period, the company recorded a net loss of $5.5 million, compared to a net loss of $27.3 million in the prior year. The improvement in net loss was primarily due to increased revenue and a reduction in operating expenses, although research and development (R&D) expenses rose significantly, reflecting ongoing investments in clinical trials and product development.

Operationally, Immunocore has made strides in expanding its market presence, with KIMMTRAK now approved in 39 countries and commercially launched in 28, including key markets such as the United States, Germany, and France. The company has treated over 2,000 patients with KIMMTRAK and other ImmTAX product candidates, which it claims is the largest clinical dataset for T cell engagers in solid tumors. The company’s employee headcount has also increased, reflecting its growth and the need for additional personnel to support its expanding operations.

In terms of financial health, Immunocore reported cash and cash equivalents of $498.4 million as of September 30, 2025, an increase from $455.7 million at the end of 2024. The company also holds marketable securities valued at $393.9 million, up from $364.6 million. The increase in cash reserves is attributed to operational cash flows and financing activities, including a private offering of $402.5 million in convertible senior notes completed in February 2024. The company anticipates that its existing cash and marketable securities will support its operations for at least the next twelve months.

Looking ahead, Immunocore expects to continue incurring significant operating losses as it invests in the development of its product pipeline and seeks regulatory approvals for additional therapies. The company remains focused on advancing its clinical programs and expanding its market reach, while also navigating potential challenges related to macroeconomic conditions and regulatory environments. The management has indicated that future funding may be necessary to support ongoing operations and growth initiatives, emphasizing the importance of strategic financing in the coming periods.